Navinci Diagnostics AB announces closing of SEK 90M Series A financing, led by Segulah Medical Acceleration with support from existing shareholders

Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.Proteins exert the majority of their physiological functions in cells and tissues by undergoing modifications and forming dynamic complexes – effects that cannot be explored by genomics,